Replies to post #1756 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA FY2Q19 results:

https://www.enanta.com/investors/news-releases/press-release/2019/Enanta-Pharmaceuticals-Reports-Financial-Results-for-its-Fiscal-Second-Quarter-Ended-March-31-2019/default.aspx

FY2Q19 royalty revenue was $39.6M, down from $69.9M in FY1Q19 (Oct-Dec 2018). ENTA’s royalty rate from ABBV resets to the lowest tier at the start of each calendar year, so ENTA’s fiscal 2Q (Jan-Mar) will always have the lowest royalty tier for a given fiscal year.

(The royalty tiers applicable to the 50% Glecaprevir component of Mavyret are shown in #msg-142808661.)

ENTA’s cash balance at 3/31/19 was $387M.

FY2Q19 GAAP EPS was $0.20, due to a tax benefit.

[DewDiligence]

On today’s CC, ABBV reiterated its guidance for 2019 Mavyret sales of $3.3B.

[DewDiligence]

ABBV’s 2Q19 HCV sales=$784M—2019 guidance lowered $3.3B—>$3.1B:

https://finance.yahoo.com/news/abbvie-reports-second-quarter-2019-114200464.html